Identification of key genes and pathways involved in trastuzumab resistance in HER۲‑positive gastric cancer through integrative bioinformatics analysis

سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 9

فایل این مقاله در 12 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-29-10_014

تاریخ نمایه سازی: 21 مهر 1405

چکیده مقاله:

Objective(s): Trastuzumab resistance limits therapeutic efficacy in HER۲-positive gastric cancer, and its systems-level regulatory architecture remains poorly characterized. This study aimed to identify key regulatory modules, biomarkers, and candidate therapeutic targets associated with trastuzumab resistance.Materials and Methods: Gene expression profiles from trastuzumab-sensitive and -resistant gastric cancer cell lines (GSE۷۷۳۴۶) were analyzed to identify differentially expressed genes (DEGs). Protein–protein interaction (PPI) networks were constructed, and hub genes were identified using topology-based methods and clustering. Functional enrichment analysis was performed using Gene Ontology and KEGG pathways. Prognostic relevance was evaluated using TCGA-STAD data via UALCAN. Drug–gene interactions were explored using DrugBank and PHAROS, followed by structural modeling and molecular docking.Results: Trastuzumab resistance was linked to transcription factor-driven reprogramming, cytoskeletal and adhesion remodeling, and receptor tyrosine kinase (RTK) bypass signaling. Eleven hub genes were identified across four functional modules potentially associated with FGFR signaling, epithelial–mesenchymal transition (EMT), and lineage plasticity. Elevated PXDN and CDH۲ expression was significantly associated with poor overall survival in TCGA-STAD. Molecular docking provided preliminary in silico evidence for potential interactions between selected compounds, including ADH-۱, AGX۵۱, artenimol, and phenethyl isothiocyanate, and candidate targets, including N-cadherin/CDH۲, ID۳, and vimentin.Conclusion: Trastuzumab resistance may involve networks related to transcriptional plasticity, adhesion dynamics, and RTK redundancy. This study provides a hypothesis-generating framework for future biomarker-guided combination strategies, which requires validation in HER۲-positive cohorts and experimental models.

کلیدواژه ها:

نویسندگان

- -

Central Laboratory, Peking University Shenzhen Hospital, Shenzhen ۵۱۸۰۳۶, P.R. China

- -

Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran

- -

Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran

- -

Nervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran

- -

School of Pharmacy, Semnan University of Medical Sciences, Semnan, Iran

- -

Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran

- -

Behestan Innovation Factory, Behestan Darou, Tehran, Iran

- -

Pharmaceutical Sciences and Cosmetic Products Research Center, Kerman University of Medical Sciences, Kerman, Iran

- -

Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran

- -

Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran

- -

Henan Key Laboratory of Medical Tissue Regeneration, School of Basic Medical Sciences, Henan Medical University, Xinxiang, Henan ۴۵۳۰۰۳, China

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric ...
  • Schulze AB, Kerkhoff A, Lenz G, Kessler T. Targeted therapies ...
  • Radford M, Abushukair H, Hentzen S, Cavalcante L, Saeed A. ...
  • Xu Q, Li J, Tang H, Bao H, Yan J, ...
  • East MP, Johnson GL. Adaptive chromatin remodeling and transcriptional changes ...
  • Li Z, Zhao H, Hu H, Shang H, Ren Y, ...
  • Duan N, Hua Y, Yan X, He Y, Zeng T, ...
  • Mottaghi-Dastjerdi N, Soltany-Rezaee-Rad M. AI-powered insights into drug resistance in ...
  • Bou Antoun N, Chioni AM. Dysregulated signalling pathways driving anticancer ...
  • Yan J, Risacher SL, Shen L, Saykin AJ. Network approaches ...
  • Rahimi H, Farzadifar E, Mottaghi-Dastjerdi N, Ghorbani A, Amerizadeh F, ...
  • Khoshdel F, Mottaghi-Dastjerdi N, Yazdani F, Salehi S, Ghorbani A, ...
  • Mottaghi-Dastjerdi N, Ghorbani A, Montazeri H, Guzzi PH. A systems ...
  • Soltany-Rezaee-Rad M, Mottaghi-Dastjerdi N, Setayesh N, Roshandel G, Ebrahimifard F, ...
  • Mottaghi-Dastjerdi N, Soltany-Rezaee-Rad M, Sepehrizadeh Z, Roshandel G, Ebrahimifard F, ...
  • Mottaghi-Dastjerdi N, Soltany-Rezaee-Rad M, Sepehrizadeh Z, Roshandel G, Ebrahimifard F, ...
  • Mottaghi-Dastjerdi N, Soltany-Rezaee-Rad M, Sepehrizadeh Z, Roshandel G, Ebrahimifard F, ...
  • Rahimi-Farsi N, Shahbazi T, Ghorbani A, Mottaghi-Dastjerdi N, Yazdani F, ...
  • Shiravi S, Mottaghi-Dastjerdi N, Shahbazi B, Ahmadi N, Soltany-Rezaee-Rad M, ...
  • Yazdani F, Mottaghi-Dastjerdi N, Shahbazi B, Ahmadi K, Ghorbani A, ...
  • Rahimi-Farsi N, Ghorbani A, Mottaghi-Dastjerdi N, Shahbazi T, Bostanian F, ...
  • Saeidi M, Pasdar A, Rahmani F, Ghorbani A, Mottaghi N, ...
  • Alvani A, Mottaghi-Dastjerdi N, Gholami A, Ghorbani A, Pazhoohesh Z, ...
  • Clough E, Barrett T, Wilhite SE, Ledoux P, Evangelista C, ...
  • Kalyan GU, Reddy DP, Chandrakanth G, Pooja B, Anitha V, ...
  • Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, ...
  • Li M, Li D, Tang Y, Wu F, Wang J. ...
  • Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, ...
  • Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, ...
  • Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, ...
  • Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, ...
  • Wiederstein M, Sippl MJ. ProSA-web: Interactive web service for the ...
  • Yuan S, Chan HS, Hu Z. Using PyMOL as a ...
  • Krishnan V. The RUNX family of proteins, DNA repair, and ...
  • Jin C, Luo Y, Liang Z, Li X, Kołat D, ...
  • Tong D, Zhao L, He K, Sun H, Cai D, ...
  • Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacopuzzi ...
  • Quintanal-Villalonga Á, Chan JM, Yu HA, Pe’er D, Sawyers CL, ...
  • Li HJ, Ray SK, Kucukural A, Gradwohl G, Leiter AB. ...
  • Corvino A, Magli E, Minale M, Autelitano A, Valente V, ...
  • Mrozik KM, Blaschuk OW, Cheong CM, Zannettino ACW, Vandyke K. ...
  • Wojnarowicz PM, Escolano MG, Huang YH, Desai B, Chin Y, ...
  • Lv H, Zhen C, Liu J, Shang P. β-Phenethyl isothiocyanate ...
  • Roy S, Kapoor A, Zhu F, Mukhopadhyay R, Ghosh AK, ...
  • Shi J, Li F, Yao X, Mou T, Xu Z, ...
  • Yuan M, Xi R, Kang Y, Kuang M-j, Ji X. ...
  • Zhang L, Goodrich DW. RB۱, cancer lineage plasticity, and therapeutic ...
  • نمایش کامل مراجع